Achieve Life Sciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Achieve Life Sciences, Inc. (ACHV) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $4.38 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.37.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2020-03-31 was $4.33.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2018-03-31 was $3.89, a 32.35% decline year-over-year.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2017-03-31 was $5.75, a 39.90% increase year-over-year.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $6.46.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2020 was $227.61, a 90.71% decline from fiscal 2019.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2019 was $2450.80, a 1424.22% increase from fiscal 2018.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2018 was $160.79, a 73.41% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.38 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $5.37 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $6.46 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $6.46 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $5.21 10-Q · filed 2025-08-07 | |||
| 2020-12-31 | $227.61 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $227.61 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $268.69 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $4.33 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | $2450.80 10-K · filed 2020-03-13 | |||
| 2018-12-31 | $160.79 10-K · filed 2019-03-14 | |||
| 2018-09-30 | $160.79 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $160.79 10-Q · filed 2018-08-08 | |||
| 2018-03-31 | $3.89 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $92.72 10-K · filed 2018-03-01 | |||
| 2017-06-30 | $3.72 10-Q · filed 2017-07-31 | |||
| 2017-03-31 | $5.75 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $1.96 10-K · filed 2017-02-23 | |||
| 2016-09-30 | $5.35 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | $5.08 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $4.11 10-Q · filed 2016-05-12 | |||
| 2015-12-31 | $14.37 10-K · filed 2017-02-23 | |||
| 2015-09-30 | $14.37 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $12.59 10-Q · filed 2015-08-13 | |||
| 2015-03-31 | $12.74 10-Q · filed 2015-05-14 | |||
| 2014-12-31 | $12.14 10-K · filed 2017-02-23 | |||
| 2014-09-30 | $11.71 10-Q · filed 2014-10-30 | |||
| 2014-06-30 | $11.92 10-Q · filed 2014-08-07 | |||
| 2013-12-31 | $13.87 10-K · filed 2016-03-09 | |||
| 2013-09-30 | $14.30 10-Q · filed 2013-11-07 | |||
| 2013-06-30 | $12.23 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $14.49 10-Q · filed 2013-05-02 | |||
| 2012-12-31 | $15.26 10-K · filed 2015-03-26 | |||
| 2012-09-30 | $15.26 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $15.26 10-Q · filed 2012-08-02 | |||
| 2011-12-31 | $41.91 10-K · filed 2014-03-11 | |||
| 2010-12-31 | $7.35 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |